Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.


Bhatt D. L. , Szarek M., Pitt B., Cannon C. P. , Leiter L. A. , McGuire D. K. , ...More

The New England journal of medicine, vol.384, pp.129-139, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 384
  • Publication Date: 2021
  • Doi Number: 10.1056/nejmoa2030186
  • Title of Journal : The New England journal of medicine
  • Page Numbers: pp.129-139

Abstract

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.